Month: April 2023

Anticipating the Future: A Guide to Smart eClinical Technology Investments


The landscape of clinical research is constantly evolving, and businesses need to keep up with the latest technology to remain competitive. However, investing in eClinical technology is not just about finding a solution for current needs, it’s equally important to think ahead and ensure that your technology investment can adapt and scale to meet future…

Read More

SkylineDx and NeraCare enter a strategic partnership to advance precision medicine for early-stage melanoma


Excerpt from the Press Release: ROTTERDAM, Netherlands and SAN DIEGO, April 20, 2023 /PRNewswire/ — SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, today announced its first non-academic strategic partnership with NeraCare GmbH from Frankfurt, Germany to co-develop a test to help life science companies…

Read More

Intergalactic Therapeutics to Present Updated Data From Its Non-Viral Gene Therapy Platform at the 2023 Retinal Cell and Gene Therapy Innovation Summit


Lead program, IG-002 targeting ABCA4 retinopathies, demonstrates durable 12-month expression of human ABCA4 protein using a single subretinal dose of DNA payload Excerpt from the Press Release: CAMBRIDGE, Mass., April 20, 2023 /PRNewswire/ — Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced today that Gayathri Ramaswamy, Ph.D., Vice President, Drug Discovery…

Read More

Elucida Oncology Announces Positive Early Phase 1 Safety Data Along with Preclinical Data for the Treatment of Brain Metastases for ELU001, an Anti-Folate Receptor Alpha C’Dot Drug Conjugate


Excerpt from the Press Release: MONMOUTH JUNCTION, N.J., April 20, 2023 (GLOBE NEWSWIRE) — Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, presented positive initial safety data from Phase 1 dose escalation trial of ELU001 (NCT05001282) in a poster titled “ELU-FRα-1: A Study to Evaluate ELU001, a C’Dot Drug…

Read More

Oblato Announces the First Enrollment in a Phase 1 Clinical Trial for an Oral Formulation of OKN-007 in Recurrent High-Grade Glioma Patients in the USA


Excerpt from the Press Release: PRINCETON, N.J., April 21, 2023 /PRNewswire/ — Oblato, Inc. (the Company), a subsidiary company of HLB Therapeutics in Korea, has announced today the first enrollment for recurrent high-grade glioma patients in a Phase 1 clinical trial in the USA with an oral formulation of its proprietary compound OKN-007.  This is…

Read More

Totus Medicines Announces First Patient Dosed in Phase 1 Trial of TOS-358 for the Treatment Of Select Solid Tumors


TOS-358 is the first highly specific, potent inhibitor of PI3Kα Excerpt from the Press Release: EMERYVILLE, Calif. , April 13, 2023 /PRNewswire/ —  Totus Medicines, the drug discovery and development company committed to ending the era of untreatable disease, announced today the dosing of the first patient in a Phase 1 clinical trial of TOS-358, the…

Read More

Verismo Therapeutics Presents STAR-101 Clinical Trial Design at the Annual Cholangiocarcinoma Foundation Conference


SynKIR™-110 T cell therapy is designed to recognize and eliminate mesothelin-overexpressing tumors in patients with advanced cholangiocarcinoma, malignant pleural mesothelioma and ovarian cancers Excerpt from the Press Release: PHILADELPHIA, April 13, 2023 /PRNewswire/ — Verismo Therapeutics, a clinical-stage CAR T company, University of Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced…

Read More

Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis


Excerpt from the Press Release: MALVERN, Pa., April 14, 2023 (GLOBE NEWSWIRE) —  Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced positive preliminary data among retinitis pigmentosa (RP) participants treated in the first two cohorts of…

Read More

Infinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K-γ and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer Research


Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced upcoming presentations including data on eganelisib by Infinity’s collaborator, Professor Judith A. Varner of the UCSD Moores Cancer Center, La Jolla, California, at…

Read More

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome


Recently published preclinical data demonstrate initial proof-of-concept for the therapeutic development of AMX0035 (sodium phenylbutyrate and taurursodiol) in Wolfram syndrome Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the first participant has been dosed in the HELIOS study, a Phase 2 clinical trial of…

Read More